StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) company profile

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.05+0.01 (+0.25%)

Close on Nov 17, 2026Market cap $336.94MP/E –Yield –

About Opus Genetics

Pharmaceutical Preparations, SIC 2834

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company that develops gene therapies and treatments for ophthalmic conditions. The company focuses on addressing inherited retinal diseases that cause severe vision impairment and blindness. Its development pipeline comprises seven adeno-associated virus gene therapy programs, led by candidates designated as OPGx-LCA5 and OPGx-BEST1, alongside programs targeting mutations in RHO, CNGB1, RDH12, NMNAT1, and MERTK. Additionally, the company develops Phentolamine Ophthalmic Solution 0.75%, an approved treatment for pharmacologically induced pupil dilation. Its therapies serve pediatric and adult patients suffering from degenerative eye disorders.

The company is incorporated in Delaware and maintains its corporate headquarters in Durham, North Carolina. Its clinical development and operational activities are conducted in the United States, addressing disorders that affect individuals across the nation and worldwide.

Summary of the business section of Opus Genetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Opus Genetics, Inc.
Founded
2018
Headquarters
Durham, NC
Address
8 Davis Drive, Suite 220 27713
Phone
(984) 884-6030
Employees
27, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Detroit, Michigan

Stock & identifiers

Ticker
IRD
Former tickers
OCUP until Nov 12, 2024; REXN until Aug 12, 2021; RNN until Aug 14, 2020
Exchange
Nasdaq
Shares outstanding
83M, Aug 3, 2026
Public float
$45.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-4 reverse, Nov 6, 2020; 1-for-12 reverse, Apr 12, 2019; 1-for-10 reverse, May 5, 2017
SEC CIK
1228627
CUSIP
67577R102
ISIN
US67577R1023
FIGI
BBG000BT34Q3
Share class FIGI
BBG001SC04V7
LEI
529900C85NBMQFSETD92
EIN
11-3516358

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
George MagrathChief Executive Officer, Director2,010,636
Benjamin R. YerxaPresident, Director670,917
Joseph K. SchachleChief Operating Officer286,673
Robert E. GagnonChief Financial Officer542,375
Ashwath JayagopalChief Scientific & Dev. Ofc.509,233
Rabourn Amy ZarembaHead of Fin. Quality Assurance188,671
Bernhard HoffmannSVP of Corp. Dev.185,446
Nirav S. JhaveriChief Financial Officer194,293
Foundation Fighting Blindness, Inc.Director9,492,171
Fighting Blindness Retinal Degeneration Fund FoundationDirector3,236,171
Cam GallagherDirector2,883,111
James S. J. ManusoDirector317,318
Jean BennettDirector259,019
Susan BentonDirector243,894
Richard J. RodgersDirector343,022
Sean AinsworthDirector321,692
Adrienne L. GravesDirector127,514

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Dr George Magrath
$1.49M$2.47M$741.63K$57–
FY2025
Mr Richard Rodgers
$0$0$741.63K$57–
FY2025
Ms Mina Sooch
$0$0$741.63K$57–
FY2024
Dr George Magrath
$889.24K-$822.03K$1.29M$34–
FY2024
Mr Richard Rodgers
$0$0$1.29M$34–
FY2024
Ms Mina Sooch
$0$0$1.29M$34–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Dr. George Magrath
Chief Executive Officer
$598.00K–$307.55K$212.05K$361.79K$14.00K$1.49M+68%
Joseph Schachle
Chief Operating Officer
$416.00K–$48.83K$33.66K$205.92K$14.00K$718.41K–
Dr. Ashwath Jayagopal
Chief Scientific and Development Officer
$416.00K$50.00K$48.83K$33.66K$205.92K$10.44K$764.85K-38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 27 full-time employees, and 1 part-time employee, with the following assignments: ten engaged in clinical research, development, and”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 22, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 22, 2024Name changeName changed from Ocuphire Pharma, Inc. to Opus Genetics, Inc.
Nov 9, 2020Name changeName changed from REXAHN PHARMACEUTICALS, INC. to Ocuphire Pharma, Inc.
Nov 6, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 6, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 6, 2020MergerRegistration of securities for a merger or exchange offer (S-4)
Jun 7, 2019ListingRegistration of securities on an exchange (Form 8-A)
Jun 7, 2019DelistingNotice of delisting from exchange (Form 25)
May 29, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 3, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
May 18, 2010Late filingNotification of late filing
Nov 9, 2009Late filingNotification of late filing
May 5, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 2, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 27, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 23, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
May 23, 2008ListingRegistration of securities on an exchange (Form 8-A)
Aug 16, 2005Late filingNotification of late filing
May 17, 2005Late filingNotification of late filing
May 16, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 29, 2005Merger voteDefinitive merger proxy statement
Apr 29, 2005Name changeName changed from CORPORATE ROAD SHOW DOT COM INC to REXAHN PHARMACEUTICALS, INC.
May 17, 2004Late filingNotification of late filing
Apr 29, 2003Name changeName changed from FERRARO FRANK to CORPORATE ROAD SHOW DOT COM INC

See a number that looks wrong?